Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Non-Current Assets (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Non-Current Assets for 14 consecutive years, with $351.2 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 4.81% to $351.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 billion through Dec 2025, up 41.08% year-over-year, with the annual reading at $351.2 million for FY2025, 4.81% down from the prior year.
  • Non-Current Assets hit $351.2 million in Q4 2025 for Corcept Therapeutics, up from $282.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $408.0 million in Q1 2025 to a low of $77.3 million in Q2 2022.
  • Historically, Non-Current Assets has averaged $192.9 million across 5 years, with a median of $157.3 million in 2021.
  • Biggest five-year swings in Non-Current Assets: plummeted 55.94% in 2022 and later surged 167.39% in 2025.
  • Year by year, Non-Current Assets stood at $157.3 million in 2021, then tumbled by 46.48% to $84.2 million in 2022, then surged by 93.5% to $162.9 million in 2023, then soared by 126.52% to $369.0 million in 2024, then decreased by 4.81% to $351.2 million in 2025.
  • Business Quant data shows Non-Current Assets for CORT at $351.2 million in Q4 2025, $282.5 million in Q3 2025, and $358.6 million in Q2 2025.